Impact of requiring re-authorization of restricted antibiotics on day 3 of therapy | Zendy

Khalid Eljaaly | Zendy; Salwa Elarabi | Zendy; Samah Alshehri | Zendy; David E. Nix | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of requiring re-authorization of restricted antibiotics on day 3 of therapy

Author(s) -

Khalid Eljaaly,

Salwa Elarabi,

Samah Alshehri,

David E. Nix

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx384

Subject(s) - antibiotics , medicine , prior authorization , authorization , intensive care medicine , pharmacology , computer science , microbiology and biotechnology , biology , computer security

Pre-authorization of restricted antibiotics is a core component of an antibiotic stewardship programme (ASP). On day 3, information about culture results and clinical status is typically available. Our objective was to compare an ASP that requires initial authorization alone with one requiring initial authorization and re-authorization on day 3 of therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research